Joint replacement recovery (hip, knee, shoulder)
Peptide considerations around elective major orthopedic surgery — pre-op optimization, anticoagulant protocols, infection surveillance, post-op rehabilitation. ~1M US arthroplasties annually.
What changes during this transition
Joint replacement is the most-protocol-heavy context in which peptide-curious users encounter the library. Roughly a million Americans undergo elective TKA or THA each year (AJRR; AAOS data), and the standard-of-care toolkit is now tightly defined: ERAS pre-op optimization (anemia, glycemic control, nutrition, smoking cessation), peri-op antibiotic prophylaxis, AAOS-guideline VTE prophylaxis (aspirin, LMWH, or DOAC for 10–35 days), and structured post-op rehabilitation. Peptides interact with all four protocols, which is why the editorial frame for this axis is constraint-first. The community framing — the 'Wolverine stack' of BPC-157 + TB-500 + sometimes CJC/ipa around orthopedic procedures — collides with three substantive safety questions: (1) angiogenic peptides during the peri-op anticoagulant window, where new vessel growth and pharmacologic anticoagulation overlap at a fresh surgical bed; (2) cellular-proliferation peptides at a site with non-trivial baseline infection risk (PJI rates 1–2% primary, 8–10% revision, ~20% one-year mortality in elderly cohorts when they occur); (3) GH-axis peptides in diabetic surgical candidates, where HbA1c above ~7.7% is itself a documented PJI multiplier. None of the peptides in this library has a randomized controlled trial in elective arthroplasty recovery. The published human evidence base is thin — one open-label retrospective intra-articular knee series for BPC-157 (Lee & Padgett 2021, n=16, no control), preclinical tendon/ligament/bone-healing models for TB-500 and IGF-1, dermatology and laser-resurfacing studies for GHK-Cu, and short-course post-fracture GH/IGF-1 trials in elderly hip-fracture cohorts. Community advocacy outruns clinical evidence by a wide margin across all five peptides. The substrate framing here mirrors that gap honestly.
Important caveat
If you are planning or recovering from elective joint replacement, the surgeon coordinating your procedure is the load-bearing decision-maker — not your peptide clinician. Many peptide protocols overlap with active surgical bleeding risk, anticoagulant prophylaxis, or infection surveillance; the standard-of-care window for starting or stopping peptides is BEFORE you book the OR and AFTER surgical hemostasis is established (typically 2–6 weeks post-op, after stitches/staples are out and surgical-site review is complete). Do NOT start a peptide cycle inside the peri-op window without your surgeon's explicit sign-off, and disclose any active peptide use during your pre-op consultations. WADA-tested masters athletes should be aware that BPC-157, TB-500, CJC/ipa, and IGF-1 LR3 are all prohibited substances.
Peptides editorially relevant to joint replacement recovery (hip, knee, shoulder)
4 peptides from the library — each evidence-tiered honestly.
- BPC-157Tier 3
Gastric pentadecapeptide
Extensively studied in rodents for tissue healing across tendon, gut, vascular, and CNS injury models. Human evidence is essentially absent — community framing far outpaces the data.
- TB-500Tier 3
Thymosin Beta-4 fragment
Animal-data peptide marketed as a tissue-repair adjunct. No published human RCTs for musculoskeletal indications.
- CJC-1295Tier 3
GHRH analog
Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.
- GHK-CuTier 2
Copper tripeptide
Strong topical evidence in skin and wound healing. Injectable systemic claims are an entirely different evidence base and tier.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.